Format

Send to

Choose Destination
Br J Cancer. 2016 Mar 1;114(5):524-31. doi: 10.1038/bjc.2015.470. Epub 2016 Feb 18.

A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.

Author information

1
Asbestos Diseases Research Institute, PO Box 3628, Rhodes, Sydney, NSW2139, Australia.
2
Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW 2050, Australia.
3
Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia.
4
Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
5
University of Western Sydney, Sydney, NSW 2150, Australia.
6
Division of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
7
Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
8
Australian School of Advanced Medicine, Macquarie University, Sydney, NSW 2109, Australia.
9
Sydney Cardiothoracic Surgeons, RPAH Medical Centre, Sydney, NSW 2050, Australia.
10
Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW 2065, Australia.
11
Australian Proteome Analysis Facility, Macquarie University, Sydney, NSW 2109, Australia.

Abstract

BACKGROUND:

We aimed to identify prognostic blood biomarkers using proteomics-based approaches in malignant pleural mesothelioma (MPM).

METHODS:

Plasma samples from 12 MPM patients were used for exploratory mass spectrometry and ELISA analyses. The significance of secreted protein acidic and rich in cysteine (SPARC) was examined in sera from a Dutch series (n=97). To determine the source of the circulating SPARC, we investigated SPARC expression in MPM tumours and healthy controls, as well as the expression and secretion from cell lines and xenografts.

RESULTS:

Secreted protein acidic and rich in cysteine was identified as a putative prognostic marker in plasma. Validation in the Dutch series showed that the median survival was higher in patients with low SPARC compared with those with high SPARC (19.0 vs 8.8 months; P=0.01). In multivariate analyses, serum SPARC remained as an independent predictor (HR 1.55; P=0.05). In MPM tumour samples, SPARC was present in the tumour cells and stromal fibroblasts. Cellular SPARC expression was higher in 5 out of 7 cell lines compared with two immortalized mesothelial lines. Neither cell lines nor xenograft tumours secreted detectable SPARC.

CONCLUSIONS:

Low circulating SPARC was associated with favourable prognosis. Secreted protein acidic and rich in cysteine was present in both tumour cells and stromal fibroblasts; and our in vitro and in vivo experiments suggest that stromal fibroblasts are a potential source of circulating SPARC.

PMID:
26889976
PMCID:
PMC4782201
[Available on 2017-03-01]
DOI:
10.1038/bjc.2015.470
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center